Yesterday, we reported on an Israeli news story that Teva was in discussions with small-cap Zenvia-maker Avanir Pharmaceuticals (AVNR). Now, Haaretz.com has a more lengthy story saying that Zenvia is in fact being reviewed by Teva. It’s difficult for us to put much credit on this rumor because according to the article, there are several companies that could be on Teva’s radar, some of which include Endo Pharmaceuticals (ENDP), Durect Corporation (DRRX) and Pain Therapeutics (PTIE).

On the positive side, however, Ken Cacciatore of Cowen has added some weight saying that Teva is seeking products or companies in the pain area…

Teva is likely to consider buying other companies, too, such as Durect, which is developing technologies for administering very strong painkillers such as oxycodone. Another buyout candidate is Pain Therapeutics, which is trading at a value of $183 million and owns the development rights to Remoxy. Analysts such as Ken Cacciatore of Cowen and Company have posited that Teva could buy competing pain treatment companies such as Endo Pharmaceuticals, trading at a value of $2 billion and King Pharmaceuticals, whose current market cap is $2.2 billion.

A Teva source did not respond to the rumors.

Stay tuned…

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts